Journal ArticleDOI
BiRD (Biaxin®[clarithromycin]/Revlimid®[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
Ruben Niesvizky,David Jayabalan,Paul J. Christos,Jessica R. Furst,Tara Naib,Scott Ely,Jessica Jalbrzikowski,Roger N. Pearse,Faiza Zafar,Karen Pekle,April LaRow,Richard Lent,Tomer M Mark,Hearn Jay Cho,Tsiporah B. Shore,Jeffrey Tepler,John G. Harpel,Michael W. Schuster,Susan Mathew,John P. Leonard,Madhu Mazumdar,Selina Chen-Kiang,Morton Coleman +22 more
Reads0
Chats0
TLDR
BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma and did not interfere with hematopoietic stem-cell harvest.About:
This article is published in Blood.The article was published on 2008-02-01. It has received 180 citations till now. The article focuses on the topics: Lenalidomide & Regimen.read more
Citations
More filters
Journal ArticleDOI
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar,Susanna Jacobus,Natalie S. Callander,Rafael Fonseca,David H. Vesole,Michael E. Williams,Rafat Abonour,David S. Siegel,Michael S. Katz,Philip R. Greipp +9 more
TL;DR: Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomid plus high-dose DexamethAsone in patients with newly diagnosed myeloma in this open-label non-inferiority trial.
Journal ArticleDOI
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji Kumar,Joseph R. Mikhael,Francis K. Buadi,David Dingli,Angela Dispenzieri,Rafael Fonseca,Morie A. Gertz,Philip R. Greipp,Suzanne R. Hayman,Robert A. Kyle,Martha Q. Lacy,John A. Lust,Craig B. Reeder,Vivek Roy,Stephen J. Russell,Kristen Detweiler Short,A. Keith Stewart,Thomas E. Witzig,Steven R. Zeldenrust,Robert J. Dalton,S. Vincent Rajkumar,P. Leif Bergsagel +21 more
TL;DR: This set of recommendations represents the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
Journal ArticleDOI
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla,Swati Goel,Sangeeta Nischal,Christoph Heuck,Kumar Vivek,Bhaskar C. Das,Amit Verma +6 more
TL;DR: Lenalidomide is a 4-amino-glutamyl analogue of thalidomides that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies.
Journal ArticleDOI
Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents
Marcio Nucci,Elias Anaissie +1 more
TL;DR: Key to the management of infection is the understanding of the specific risk factors and periods during which patients are at risk; this allows the anticipation of the likely pathogen(s) and the application of risk-adjusted prophylactic and treatment strategies.
Journal ArticleDOI
Guidelines for the diagnosis and management of multiple myeloma 2011.
Jennifer M. Bird,Roger G. Owen,Shirley D'Sa,John A. Snowden,Guy Pratt,John Ashcroft,Kwee Yong,Gordon Cook,Sylvia Feyler,Faith E. Davies,Gareth J. Morgan,Jamie Cavenagh,Eric Low,Judith Behrens,UK Myeloma Forum +14 more
TL;DR: The results of a multicenter randomized phase II trial of thalidomide and prednisone mainte- nance therapy for multiple myeloma after autol- ogous stem cell transplant are published.
References
More filters
Journal ArticleDOI
Optimal two-stage designs for phase II clinical trials.
TL;DR: Two-stage designs that are optimal in the sense that the expected sample size is minimized if the regimen has low activity subject to constraints upon the size of the type 1 and type 2 errors are presented.
Journal ArticleDOI
International uniform response criteria for multiple myeloma
Brian G.M. Durie,J L Harousseau,Jesús F. San Miguel,J. Bladé,Bart Barlogie,Kenneth C. Anderson,Morie A. Gertz,Meletios A. Dimopoulos,Johan Westin,Pieter Sonneveld,Heinz Ludwig,G. Gahrton,Meral Beksac,John Crowley,Andrew Belch,M. Boccadaro,Ingemar Turesson,Douglas E. Joshua,David H. Vesole,Robert A. Kyle,Raymond Alexanian,Guido Tricot,M. Attal,Giampaolo Merlini,R. L. Powles,Paul G. Richardson,K. Shimizu,Patrizia Tosi,Gareth J. Morgan,S V Rajkumar +29 more
TL;DR: The European Group for Blood and Bone Marrow Transplant/International Bone Marrows Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system to adequately assess clinical outcomes in myeloma.
Journal ArticleDOI
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
Joan Bladé,Diana Samson,Donna E. Reece,Jane F. Apperley,Bo Björkstrand,Gösta Gahrton,Morie A. Gertz,Sergio Giralt,SUNDARr Jagannath,David H. Vesole +9 more
TL;DR: New criteria for response and progression have been developed as a result of discussions between representatives of the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and representatives ofThe Myelomas Working Committee of the Autologousblood and marrow transplant Registry (ABMTR) and the International Bone Marrowtransplant Registry (IBMTR).
Journal ArticleDOI
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Michel Attal,Jean-Luc Harousseau,Thierry Facon,François Guilhot,Chantal Doyen,Jean-Gabriel Fuzibet,Mathieu Monconduit,Cyrille Hulin,Denis Caillot,Reda Bouabdallah,Laurent Voillat,Jean-Jacques Sotto,Bernard Grosbois,Régis Bataille +13 more
TL;DR: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Related Papers (5)
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Maria-Victoria Mateos,Kenneth C. Anderson,Dixie Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Paul G. Richardson +20 more